← All trials
NCT01483560
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2011
- Primary completion
- Mar 19, 2017
- Completion date
- Apr 18, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 502
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of GlasgowLead sponsor
- University of GlasgowOverall official - principal investigator
- University of DundeeStudy director
- University of DundeeCollaborator
- University of MelbourneCollaborator
- University of GlasgowCollaborator
- University of LondonCollaborator
- University of WisconsinCollaborator
- Juvenile Diabetes Research FoundationCollaborator
- Itamar-Medical, IsraelCollaborator
- Maastricht UniversityCollaborator
- Merck SeronoCollaborator
- University of GlasgowReponsible party - principal investigator
- University of Western OntarioCollaborator
- Steno Diabetes Center CopenhagenCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.